BioPorto (BIOPOR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioPorto (BIOPOR) has a cash flow conversion efficiency ratio of -0.249x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr-15.68 Million ≈ $-2.45 Million USD) by net assets (Dkr63.01 Million ≈ $9.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of BioPorto to measure how many days the company can operate on defensive assets alone.
BioPorto - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how BioPorto's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BioPorto Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioPorto ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Streamex Corp
NASDAQ:STEX
|
-0.023x |
|
Fluent Inc
NASDAQ:FLNT
|
-0.350x |
|
KEYEAST.Co.Ltd
KQ:054780
|
-0.060x |
|
CAB Cakaran Corporation Bhd
KLSE:7174
|
0.245x |
|
ChampionsGate Acquisition Corporation Class A Ordinary Share
NASDAQ:CHPG
|
0.000x |
|
Agrify Corp
NASDAQ:AGFY
|
-0.459x |
|
Sarla Performance Fibers Limited
NSE:SARLAPOLY
|
0.091x |
|
Ecos India Mobility & Hospitality Ltd
NSE:ECOSMOBLTY
|
0.088x |
Annual Cash Flow Conversion Efficiency for BioPorto (2000–2025)
The table below shows the annual cash flow conversion efficiency of BioPorto from 2000 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of BioPorto.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Dkr63.01 Million ≈ $9.86 Million |
Dkr-77.07 Million ≈ $-12.06 Million |
-1.223x | +0.82% |
| 2024-12-31 | Dkr67.78 Million ≈ $10.60 Million |
Dkr-83.58 Million ≈ $-13.08 Million |
-1.233x | -33.78% |
| 2023-12-31 | Dkr60.16 Million ≈ $9.41 Million |
Dkr-55.46 Million ≈ $-8.68 Million |
-0.922x | -23.33% |
| 2022-12-31 | Dkr70.22 Million ≈ $10.99 Million |
Dkr-52.48 Million ≈ $-8.21 Million |
-0.747x | +46.80% |
| 2021-12-31 | Dkr45.96 Million ≈ $7.19 Million |
Dkr-64.58 Million ≈ $-10.10 Million |
-1.405x | -298.07% |
| 2020-12-31 | Dkr100.91 Million ≈ $15.79 Million |
Dkr-35.62 Million ≈ $-5.57 Million |
-0.353x | +85.15% |
| 2019-12-31 | Dkr25.32 Million ≈ $3.96 Million |
Dkr-60.16 Million ≈ $-9.41 Million |
-2.376x | -251.29% |
| 2018-12-31 | Dkr56.20 Million ≈ $8.79 Million |
Dkr-38.01 Million ≈ $-5.95 Million |
-0.676x | -28.99% |
| 2017-12-31 | Dkr56.07 Million ≈ $8.77 Million |
Dkr-29.40 Million ≈ $-4.60 Million |
-0.524x | -18.13% |
| 2016-12-31 | Dkr44.29 Million ≈ $6.93 Million |
Dkr-19.66 Million ≈ $-3.08 Million |
-0.444x | -19.14% |
| 2015-12-31 | Dkr44.48 Million ≈ $6.96 Million |
Dkr-16.57 Million ≈ $-2.59 Million |
-0.373x | +33.77% |
| 2014-12-31 | Dkr28.69 Million ≈ $4.49 Million |
Dkr-16.14 Million ≈ $-2.52 Million |
-0.563x | -44.91% |
| 2013-12-31 | Dkr42.86 Million ≈ $6.71 Million |
Dkr-16.64 Million ≈ $-2.60 Million |
-0.388x | -102.92% |
| 2012-12-31 | Dkr-1.15 Million ≈ $-179.93K |
Dkr-15.28 Million ≈ $-2.39 Million |
13.287x | +484.76% |
| 2011-12-31 | Dkr3.94 Million ≈ $616.44K |
Dkr-13.61 Million ≈ $-2.13 Million |
-3.453x | +14.59% |
| 2010-12-31 | Dkr3.31 Million ≈ $517.72K |
Dkr-13.38 Million ≈ $-2.09 Million |
-4.043x | -368.99% |
| 2009-12-31 | Dkr15.41 Million ≈ $2.41 Million |
Dkr-13.29 Million ≈ $-2.08 Million |
-0.862x | +2.57% |
| 2008-12-31 | Dkr15.50 Million ≈ $2.43 Million |
Dkr-13.72 Million ≈ $-2.15 Million |
-0.885x | -84.47% |
| 2007-12-31 | Dkr29.45 Million ≈ $4.61 Million |
Dkr-14.13 Million ≈ $-2.21 Million |
-0.480x | -62897.70% |
| 2006-12-31 | Dkr-17.62 Million ≈ $-2.76 Million |
Dkr-13.46K ≈ $-2.11K |
0.001x | -83.18% |
| 2005-12-31 | Dkr-3.06 Million ≈ $-478.13K |
Dkr-13.88K ≈ $-2.17K |
0.005x | -99.19% |
| 2000-12-31 | Dkr894.00K ≈ $139.87K |
Dkr503.00K ≈ $78.70K |
0.563x | -- |
About BioPorto
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination o… Read more